Please login to the form below

Not currently logged in
Email:
Password:

filibuvir

This page shows the latest filibuvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie gets 'breakthrough' status for hepatitis C regimen

AbbVie gets 'breakthrough' status for hepatitis C regimen

In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

Latest news

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    pipeline. The decision to drop filibuvir, reported by the Wall Street Journal on Friday, effectively means that Pfizer has withdrawn from the race to develop a non-interferon-based regimen for ... Filibuvir (also known as PF-00868554) is a non-nucleoside

  • HCV hope on the horizon

    Tibotec). . Among the polymerase inhibitors, the most advanced in development is Pfizer's non-nucleoside compound filibuvir at phase II.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics